The invention relates to an aqueous ophthalmic pharmaceutical composition comprising:a) at least 0.4% w/v of bilastine, of formulaor a pharmaceutically acceptable salt or solvate thereof, wherein the bilastine salt or solvate thereof is completely dissolved in the pharmaceutical composition；b) at least one β-cyclodextrin； andc) at least one pharmaceutically acceptable water-soluble gelling agent；and wherein the pH is comprised between 4 and 9.and its use in the treatment and/or prevention of conditions mediated by H1histamine receptor, such as allergic disorders or diseases. The invention relates to the treatment and/or prevention of allergic conjunctivitis.本發明關於一種水性眼用醫藥組成物，其包含：a) 至少0.4% w/v的下式之比拉斯汀(bilastine)或其醫藥上可接受的鹽或溶劑合物，其中該比拉斯汀或其鹽或溶劑合物完全溶解在該醫藥組成物中；b) 至少一種β-環糊精；及c) 至少一種醫藥上可接受的水溶性膠凝劑；及其中該pH值範圍在4到9之間，及關於其用於治療及/或預防容易藉由H1組織胺受體媒介的病況(諸如過敏性病症或疾病)之用途。本發明關於過敏性結膜炎之治療及/或預防。
